Brief: Axsome Therapeutics Provides Update On The New Drug Application For Axs-14 For Fibromyalgia

Axsome Therapeutics

09/06/2025 12:22

June 9 (Reuters) - Axsome Therapeutics Inc AXSM.O:

AXSOME THERAPEUTICS PROVIDES UPDATE ON THE NEW DRUG APPLICATION (NDA) FOR AXS-14 FOR THE MANAGEMENT OF FIBROMYALGIA

AXSOME THERAPEUTICS INC - RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR AXS-14

AXSOME THERAPEUTICS INC - FDA FINDS NDA FOR AXS-14 INSUFFICIENTLY COMPLETE FOR REVIEW

AXSOME THERAPEUTICS INC - TO CONDUCT ADDITIONAL CONTROLLED TRIAL FOR AXS-14 IN Q4 2025

Source text: ID:nGNX1PxNGd

Further company coverage: AXSM.O

 ((Reuters.Briefs@thomsonreuters.com;))